{"schema_version":"secwatch.filing_event.v1","accession":"0001999371-24-006472","form_type":"8-K","ticker":"TNXP","cik":"0001430306","company_name":"Tonix Pharmaceuticals Holding Corp.","filed_at":"2024-05-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.382876+00:00","generated_at":"2026-06-01T09:41:56.157037+00:00","sec_items":["2.05","2.06","5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Tonix cuts 23 employees, closes Mass. facility; shareholders approve reverse stock split","bullets":["Workforce reduction of 23 FTEs and decommissioning of Advanced Development Center in Mass. by June 7, 2024.","No material charge expected for restructuring; impairment amount not yet determinable.","Shareholders (61.6% of shares) elected 8 directors, ratified EisnerAmper as auditor.","Approved reverse stock split of 1:2 to 1:50, board to set exact ratio within one year.","Approved repricing of up to 93.4M warrants issued Aug-Dec 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001999371-24-006472","json":"https://secwatch.observer/filing/0001999371-24-006472.json","markdown":"https://secwatch.observer/filing/0001999371-24-006472.md","text":"https://secwatch.observer/filing/0001999371-24-006472.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1430306/000199937124006472/0001999371-24-006472-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1430306/000199937124006472/tnpx_8k-052224.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T09:41:56.157037+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"62e277b5197b723059ea73dad36d8db39b245000","claim":"Tonix Pharmaceuticals Holding Corp. announced a restructuring affecting Advanced Development Center (\"ADC\") in Massachusetts (23 full-time employees).","evidence_excerpt":"Tonix Pharmaceuticals Holding Corp. (the “Company”) plans to reduce its workforce by 23 full-time employees and decommission its Advanced Development Center (“ADC”) in Massachusetts by June 7, 2024, to align the Company’s capital and human resources with its previously announced strategic prioritization of its TonmyaTM (TNX-102 SL cyclobenzaprine HCl sublingual tablet) product candidate for the management of fibromyalgia","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1430306/000199937124006472/0001999371-24-006472-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Affected area","value":"Advanced Development Center (\"ADC\") in Massachusetts"},{"label":"Headcount","value":"23 full-time employees"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}